Doctor profile · Federal record
Dr. Mohammad Oreizi Esfahani, MD
Rheumatology Physician (CMS: Rheumatology) · Westminster, MD
- NPI 1821085317
- Accepts Medicare
- MIPS 75.0 / 100 · 2023
- 37 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
531 Old Westminster Pike Ste 202
Westminster, MD 211576276
(410) 465-0576
Credentials & registration
- NPI registered
- September 2005 — 21 yrs on file
- Profile last updated
- July 8, 2022
- Year of graduation
- 1989 — 37 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Maryland #D44533
- Medicaid
- MD #055503700
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1821085317. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
28,866
Distinct HCPCS
10
Medicare allowed
$886,773
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0897 |
Injection, denosumab, 1 mg | 10,980 | 118 | $23 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 5,871 | 11 | $13 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 4,900 | 16 | $42 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 4,730 | 32 | $32 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 642 | 399 | $135 | |
J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 262 | 35 | $1 | |
96372 |
Injection of drug or substance under skin or into muscle | 215 | 141 | $15 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 187 | 163 | $96 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 176 | 73 | $142 | |
77080 |
Dxa bone density measurement of hip, pelvis, spine | 169 | 169 | $41 |
In context: peer comparison
Among 1 peers in Westminster Rheumatology Physician, average services per provider: 1,374. This provider delivers 21× the peer median.Open Payments
Industry payments received
All-time total
$659
Transactions
40
Manufacturers
10
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen INC. | 11 | $225.35 | |
| Abbvie INC. | 19 | $196.26 | |
| Mallinckrodt Hospital Products INC. | 2 | $51.62 | |
| Janssen Biotech, INC. | 2 | $50.76 | |
| Aurinia Pharma U.S., INC. | 1 | $27.39 | |
| Fresenius Kabi USA, LLC | 1 | $24.30 | |
| Genzyme Corporation | 1 | $23.83 | |
| Novartis Pharmaceuticals Corporation | 1 | $20.94 | |
| Pfizer INC. | 1 | $19.44 | |
| Ucb, INC. | 1 | $19.13 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,334
Patients
434
Total drug cost
$567,472
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 351 | 140 | $3,078 |
| Methotrexate (Methotrexate Sodium) | Brand | 287 | 97 | $12,269 |
| Hydroxychloroquine Sulfate | Generic | 229 | 84 | $12,309 |
| Alendronate Sodium | Generic | 96 | 36 | $1,328 |
| Allopurinol | Generic | 47 | 18 | $651 |
| Celecoxib | Generic | 46 | 13 | $1,364 |
| Meloxicam | Generic | 43 | 20 | $501 |
| Gabapentin | Generic | 37 | 14 | $823 |
| Enbrel Sureclick (Etanercept) | Brand | 35 | 0 | $290,069 |
| Duloxetine Hcl | Generic | 32 | 0 | $1,186 |
Frequently asked questions
What is Dr. Mohammad Oreizi Esfahani's medical specialty?
Dr. Mohammad Oreizi Esfahani practices Rheumatology Physician in Westminster, MD.
Where does Dr. Mohammad Oreizi Esfahani practice?
Dr. Mohammad Oreizi Esfahani practices at 531 Old Westminster Pike Ste 202, Westminster, MD 211576276. Office phone: 4104650576.
What is Dr. Mohammad Oreizi Esfahani's NPI?
Dr. Mohammad Oreizi Esfahani's National Provider Identifier (NPI) is 1821085317, issued by NPPES.
Does Dr. Mohammad Oreizi Esfahani accept Medicare assignment?
Yes. Dr. Mohammad Oreizi Esfahani accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Mohammad Oreizi Esfahani commonly perform?
Top Medicare-reported procedures in 2023: Injection, denosumab, 1 mg (HCPCS J0897); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129). Source: CMS Medicare Physician & Other Practitioners file.